Serum - Protection from birth onwards
Medellín, Colombia, 22 April 2026: VaxThera SAS (www.vaxthera.com), a Colombian-based biotechnology company, announced a strategic collaboration with Serum Institute of India (SII), a Cyrus Poonawalla group company and the world's largest vaccine manufacturer, to strengthen vaccine manufacturing and health security in Colombia.
This collaboration represents a historic step forward for Colombia. Together, VaxThera and the Serum Institute of India will launch a collaborative program focused initially on critical vaccines of major importance to the national immunization program. The alliance is designed to ensure that populations in need of access to vaccines benefit the most from a reliable, locally produced supply.
"At VaxThera, we are committed to restoring and strengthening vaccine manufacturing in Colombia, ensuring that the country can rely on its own scientific and industrial capabilities to protect public health. Revitalizing local production is essential not only for responding to future health emergencies but also for driving research, innovation, and equitable access to vaccines. This effort requires collaboration—science alone cannot transform health systems without strong partnerships. By working with national and international allies, we are building a sustainable biomanufacturing ecosystem that will benefit Colombia for generations to come," commented Professor Jorge Osorio, VaxThera’s CEO.
Through this collaboration, VaxThera and SII will collaborate with respect to the development of vaccines and biologicals in Colombia, reinforcing the region’s ability to ensure a stable supply, reduce dependence on external markets, and strengthen preparedness against emerging health threats. In a world where pandemics, supply chain disruptions, and geopolitical challenges can rapidly impact global health systems, regional manufacturing capacity has become a cornerstone of health security.
At the heart of this collaboration lies a shared commitment to quality, accessibility, and long-term sustainability. SII’s global reputation has been built on delivering safe, affordable, and effective vaccines at scale while maintaining the highest international quality standards. VaxThera brings to the alliance a rapidly growing biotechnology ecosystem in Colombia, including advanced laboratories, a large-scale GMP manufacturing facility, and strong scientific collaborations with academic institutions and global partners. Together, both organizations aim not only to supply vaccines but also to build a resilient ecosystem for prevention and innovation in the region.
"We are deeply grateful to the Serum Institute of India for believing in VaxThera, in our project, and in our long-term vision," said Professor Juan Pablo Hernandez, COO of VaxThera. "This collaboration demonstrates that when institutions from different parts of the world share a common purpose, it is possible to build solutions that transcend borders and create lasting impact".
While the immediate focus is on expanding access to essential vaccines for immunization programs, the collaboration also reinforces Colombia’s capacity to respond rapidly to emerging health threats. The infrastructure, expertise, and collaborations being developed today will position the region to play a more active role in addressing future pandemics and global health emergencies.
Through collaboration with Serum Institute of India, VaxThera takes another step toward advancing health independence, health security, and equitable access to life-saving technologies for millions of people in Colombia. This collaboration reflects a shared belief that science, when combined with trust, collaboration, and long-term commitment, can transform the future of global health.
About VaxThera
VaxThera is a SURA company focused on the research, development, and manufacturing of vaccines and advanced biological products. Based in Colombia, the company leverages cutting edge scientific platforms and global partnerships to strengthen regional biopharmaceutical capabilities and contribute to global health security.
About Seguros SURA Colombia
With over 80 years of experience, this subsidiary of Suramericana S.A. offers a wide portfolio of insurance solutions and services that deliver sustainable well-being and competitiveness to 12 million unique clients in Colombia through trend and risk management.
About Serum Institute of India
Serum Institute of India Pvt. Ltd, is a global leader in vaccine manufacturing, dedicated to providing affordable vaccines worldwide. Present across 170+ countries, including the US, UK, and Europe, SII holds the distinction of being the world’s largest vaccine manufacturer. SII’s multifunctional production and one-of-the-largest facility in Manjri, Pune, with an annual capacity of 4 billion doses, has saved over 30 million lives over the years.
Founded in 1966, SII’s primary mission is to produce life-saving immunobiological drugs, with a particular emphasis on affordability and accessibility. Guided by a strong commitment to improving global health, the company has played a pivotal role in reducing the prices of essential vaccines, such as Diphtheria, Tetanus, Pertussis, HIB, BCG, r-Hepatitis B, Measles, Mumps, and Rubella. Notably, they are the manufacturers of ‘Pneumosil,’ the world’s most affordable PCV, and the first indigenous qHPV vaccine in India. Moreover, SII has been at the forefront of the global fight against COVID- 19, delivering over 2 billion doses of COVID-19 vaccine worldwide.
To further expand its global presence and ensure widespread vaccine availability, SII has established Serum Life Sciences Ltd, a subsidiary in the UK. Through relentless pursuit of innovation, SII continues to champion the cause of affordable vaccines, making a positive impact on the lives of millions worldwide. www.seruminstitute.com